Abcam, ab239948, Anti-FEN1 antibody [EPR4460(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FEN1 antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR4460(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab239948 is the carrier-free version of
ab109132
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Flap Endonuclease 1 known as FEN1 or FEN-1 is an important protein involved in DNA replication and repair. This protein shows a molecular weight of approximately 42 kDa. FEN1 functions as an endonuclease where it removes 5’ overhanging flaps in DNA products that occur during DNA replication and repair processes. It expresses in a wide range of human tissues with significant presence in the nucleus where DNA synthesis mainly occurs.
Biological function summary
FEN1 plays an important role in the Okazaki fragment maturation during lagging strand synthesis and long-patch base excision repair. FEN1 is not a solitary actor; it forms a part of larger complexes essential for maintaining genomic stability. It works closely with proliferating cell nuclear antigen (PCNA) to enhance its function and to interact with other proteins essential for the stability of the DNA.
Pathways
DNA replication and repair processes heavily rely on the activity of FEN1. It’s a component of the DNA replication fork protection and repair pathway and interacts with other proteins such as DNA polymerase and DNA ligase I to complete the repair process. Efficient DNA replication ensures accurate genomic duplication preventing mutations that could lead to severe cellular malfunction.
FEN1 is linked to the development of cancer and neurodegenerative diseases like Huntington's disease. FEN1 mutations or malfunction can result in genomic instability and an increased risk of tumorigenesis. In the context of neurodegenerative diseases deficiencies in FEN1 activity may disrupt the repair of oxidative DNA damage which is an important feature of disorders like Huntington's. These insights highlight the need for further research into FEN1's role and interactions to develop potential therapeutic strategies.